Testing is the weak link in the HIV care pathway in France. Despite new recommendations and a broader range of testing options, the increase in the number of tests is not enough to rapidly reduce the time between infection and diagnosis. Since July 1, 2019, the “Au labo sans ordo” (ALSO) program has offered HIV testing without a prescription and at no cost in all private medical laboratories in Paris and the Alpes-Maritimes region. Its goal is to improve access to testing as a complement to existing services. The pilot program is supported by a multidimensional evaluation framework. This article describes its implementation and the results of the first six months in terms of uptake of the service and its impact on overall HIV testing activity in the two departments. For the first half of the year, ALSO tests accounted for 8% of all laboratory tests: in Paris, 15,583 ALSO tests out of 175,938 prescribed tests in 157 laboratories; and in the Alpes-Maritimes, 4,853 ALSO tests out of 54,082 prescribed tests in 106 laboratories. A comparison between the second half of 2019 and the second half of 2018 shows a clear increase in the volume of tests reimbursed by the health insurance system to laboratories. Information gathered from CeGIDDs (Free Centers for Information, Screening, and Diagnosis) does not indicate a shift of their users toward ALSO. The rates of ALSO HIV-positive tests (2.0 and 1.6 per 1,000 in Paris and the Alpes-Maritimes, respectively) fall between those of prescribed tests (3.0 and 2.3 per 1,000) and those of the CeGIDDs (5.7 and 5.4 per 1,000). These encouraging interim results have led to the extension of the pilot program through the end of 2020, given the COVID-19 crisis.